Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement
Protalix BioTherapeutics, Inc. (DE) (PLX)
NASDAQ:AMEX Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=101161&p=irol-irhome
Company Research
Source: PR Newswire
Partnership combines Protalix's rare disease and biologics expertise with Secarna's AI–powered OligoCreator® platform to jointly develop pharmaceutical candidates for rare renal indicationsProtalix is granted an exclusive option to license any active compounds derived from the research for potential clinical development and commercializationCARMIEL, Israel and MARTINSRIED, Germany, Dec. 17, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with significant unmet needs, and Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, today announced that they have entered into a collaboration and option agreement. Under this agreement, the companies have agreed to partner in the discovery of novel antisense oligonucleotide (ASO) therapies agains
Show less
Read more
Impact Snapshot
Event Time:
PLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PLX alerts
High impacting Protalix BioTherapeutics, Inc. (DE) news events
Weekly update
A roundup of the hottest topics
PLX
News
- Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement [Yahoo! Finance]Yahoo! Finance
- Protalix BioTherapeutics (NYSE:PLX) had its price target lowered by analysts at HC Wainwright from $15.00 to $12.00. They now have a "buy" rating on the stock.MarketBeat
- Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business ResultsPR Newswire
- Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025PR Newswire
- PLX Investors Have Opportunity to Join Protalix BioTherapeutics, Inc. Fraud Investigation with the Schall Law FirmGlobeNewswire
PLX
Earnings
- 11/13/25 - Miss
PLX
Sec Filings
- 11/19/25 - Form 4
- 11/13/25 - Form 10-Q
- 11/13/25 - Form 8-K
- PLX's page on the SEC website